Why A Northstar Analyst Is Bullish On This Disruptive MedTech Company
A strong value proposition and high retention rate have turned Northland Capital Markets bullish on Biotricity, Inc (OTC: BTCY).
The Biotricity Analyst: Analyst Jason Wittes initiated coverage on Biotricity with an Outperform rating, setting a share price target of $7.